That means that there is still no clear evidence regarding whether or not it causes cancer in humans
Distributed by Tribune Content Agency, LLC.
The complaint titled Roderick Shirley v
Key Takeaways Semaglutide produces clinically significant weight loss the STEP 1 trial demonstrated a mean 14.9% body weight reduction at 68 weeks with the 2.4 mg dose The dose escalation schedule is medically necessary, not optional rushing it leads to severe GI side effects that cause most treatment discontinuations Semaglutide is a long-term medication weight returns if treatment is stopped, as shown in the STEP 1 extension trial It carries real contraindications including a family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe GI disease Drug interactions with oral medications are clinically relevant your full medication list must be reviewed by a pharmacist or physician before starting Maximum benefit requires combining semaglutide with a healthy diet and physical activity it reduces appetite, but it does not replace lifestyle modification References Wilding JPH, Batterham RL, Calanna S, et al
GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/beta-Catenin Signaling Pathway
